McKesson Recalls bupropion Hydrochloride Extended-Release Tablets Due to Dissolution Failure
McKesson Packaging Services is recalling 187 cartons of bupropion Hydrochloride Extended-Release Tablets, 150 mg, because they failed USP dissolution test requirements.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences. The specific hazard is a quality control failure (dissolution) rather than a direct physical injury risk.
Plain-English summary
McKesson Packaging Services is recalling 187 cartons of bupropion Hydrochloride Extended-Release Tablets (XL), 150 mg. The product is identified by NDC 63739-449-10, Lot # 0074583, and an expiration date of 03/12. The tablets were manufactured by CMIC-VPS Corporation and distributed nationwide.
The recall was initiated because the product failed USP Dissolution Test Requirements, specifically showing possible out-of-specification dissolution results at the 8-hour stability testing point. This indicates the tablets may not release the medication as intended.
Consumers should stop using the recalled product and return it to their pharmacy or contact McKesson Packaging Services for a replacement or refund. Healthcare providers should verify their inventory against the specific lot and expiration date listed above.
The recalled product
- Product
- buPROPion Hydrochloride Extended-Release Tablets (XL), 150 mg, UD 100 Tablets (10 x 10) per carton, Rx only, Mfg By: CMIC-VPS Corporation, Cranbury, New Jersey 08512; blister barcode N (01)003 63739 449 10 7, Dist By: McKesson Packaging, Concord, NC 28027; NDC 63739-449-10, car
- Manufacturer
- McKesson Packaging Services
- Category
- Drug — Prescription Medication
- Affected units
- 187
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 0074583
- Exp. Date 03/12
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by McKesson Packaging Services under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · McKesson Packaging Services
See all →- ModerateMcKesson Recalls Diltiazem CD Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- LowMcKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateMcKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateRanitidine Tablets Recalled for Failed Stability Specifications
FDA (Drugs) · 2018-03-14
- ModerateMcKesson Recalls Subpotent Megestrol Acetate Oral Suspension
FDA (Drugs) · 2018-02-14
Same hazard · quality control
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateDuoGlide Short-Term Dialysis Catheter recall due to deficient manufacturing
FDA (Devices) · 2026-07-08
- ModeratedirectCHECK whole blood control labeled with incorrect performance range
FDA (Devices) · 2026-06-24
- HighAmyloid plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11
- HighpTau 217 plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11